Recombinant Human CD20 protein (His Tag)

ED50

10-40 ng/mL

Species

Human

Purity

>95 %, SDS-PAGE

GeneID

931

Accession

P11836-1

Cat No : Eg0195

Print datasheet

Synonyms

B1, Bp35, CD20, CVID5, LEU-16, MS4A1, MS4A2, S7



Technical Specifications

Purity >95 %, SDS-PAGE
Endotoxin Level <1.0 EU/μg protein, LAL method
Biological Activity
Immobilized Rituximab at 0.5 μg/mL (100 μL/well) can bind Human CD20 (His tag) with a linear range of 10-40 ng/mL.
Source HEK293-derived Human CD20 protein Glu213-Pro297 (Accession# P11836-1) with a His tag at the N-terminus.
Predicted Molecular Mass 10.6 kDa
SDS-PAGE 20-23 kDa, reducing (R) conditions
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • 12 months from the date of receipt, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD20 is a B-lymphocyte surface molecule that is widely expressed during B-cell ontogeny but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Its function is to enable optimal B-cell immune response, specifically against T-independent antigens. CD20 functions as calcium-permeable cation channel. It is involved in the regulation of B-cell activation and proliferation.

References:

1.Dong Fang. et al.(2005) Cancer Res. 65(20): 9328-37. 2.Pedersen M. et al.(2008) Biochem Biophys Res Commun. 377(1): 98-103. 3.Maria J Polyak. et al.(2008) J Biol Chem. 283(27): 18545-52. 4.Taco W Kuijpers. et al.(2010) J Clin Invest. 120(1): 214-22. 5.Gabriela Pavlasova. et al.(2018) Leukemia. 32(9): 2028-2031.